Recruiting Pulmonary Hypertension Studies in Bristol
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis....
Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macula...
About Pulmonary Hypertension Clinical Trials in Bristol
Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.
There are currently 2 pulmonary hypertension clinical trials recruiting participants in Bristol, VA. These studies are seeking a combined 187 participants. Research is being sponsored by Uniquity One (UNI), University of Kentucky. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Hypertension Clinical Trials in Bristol — FAQ
Are there pulmonary hypertension clinical trials in Bristol?
Yes, there are 2 pulmonary hypertension clinical trials currently recruiting in Bristol, VA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Bristol?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Bristol research site will contact you about next steps.
Are clinical trials in Bristol free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Bristol studies also compensate for your time and travel.
What pulmonary hypertension treatments are being tested?
The 2 active trials in Bristol are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.
Data updated March 2, 2026 from ClinicalTrials.gov